Mark Richard Ashton

Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia.

UniQuest Pty Ltd. operates as a commercialization company of The University of Queensland. It specializes in industry-university collaborations, global technology transfer, and provide access to UQ's world-class expertise, intellectual property, and facilities. The company was founded in July 1984 and is headquartered in Brisbane, Australia.

Dimerix Bioscience Pty Ltd. engages in the development and commercialization of drug therapies and drug discovery tools. It deals with clinical research organizations to progress its programs through clinical studies. It focuses on the clinical development of its therapeutic product DMX200 which is targeted to treat patients with chronic kidney disease. The company was founded by James Howard Williams on December 16, 2004 and is headquartered in Melbourne, Australia.

Helmedix Pty Ltd. develops novel therapies for autoimmune diseases. It uses peptides derived from helminthes parasite to treat rheumatoid arthritis, colitis, psoriasis and multiple sclerosis. The company was founded by Andrew Hutchinson on December 1, 2012 and is headquartered in Melbourne, Australia.